title: The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis.
abstract: Aminoguanidine is an investigational agent that may slow or prevent many diabetes-related complications. Since the elimination of aminoguanidine is dependent on renal function, its pharmacokinetics was investigated in eight chronic renal failure patients maintained on hemodialysis. Each patient received 300 mg of aminoguanidine hydrochloride during both an interdialytic and an intradialytic period. During the interdialytic period, the maximum aminoguanidine concentration (Cmax) and time to reach Cmax was 4.5 micrograms/mL and 1.5 hours, respectively. The terminal elimination half-life in these patients was prolonged (37.9 hours). The renal clearance was 2.1 mL/min. Only 8.7% of the administered dose was recovered unchanged in the urine, which is markedly reduced from what is recovered in urine in subjects with normal renal function. There was a positive correlation between the renal clearance of aminoguanidine and the patients' residual renal function (P < 0.05). During hemodialysis, the half-life of aminoguanidine was shortened to 3.9 hours. The hemodialysis clearance of aminoguanidine was 203.6 mL/min. After cessation of hemodialysis, a significant rebound in plasma aminoguanidine concentrations (mean, 39%) was observed. Thus, the dose of aminoguanidine hydrochloride will need to be significantly reduced in patients with end-stage renal disease. Given the interdialytic and intradialytic pharmacokinetics of aminoguanidine, three times weekly dosing after each hemodialysis session is suggested.
authors.affiliation: Department of Medicine, Hennepin County Medical Center, Minneapolis, MN 55404.
authors.forename: E F
authors.initials: EF
authors.lastname: Foote
authors.forename: Z M
authors.initials: ZM
authors.lastname: Look
authors.forename: P
authors.initials: P
authors.lastname: Giles
authors.forename: W F
authors.initials: WF
authors.lastname: Keane
authors.forename: C E
authors.initials: CE
authors.lastname: Halstenson
mesh_terms: D003928:Diabetic Nephropathies / Q000378:metabolism* / Q000628:therapy; D005260:Female; D006146:Guanidines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
chemical_list: D006146:Guanidines; C004479:pimagedine